RobinHood race from $2,500 to $250,000
- Thread starter Fermion
- Start date
harley
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
It's sort of like ROFLMFAO.
bobandsherry
Thinks s/he gets paid by the post
- Joined
- Nov 24, 2015
- Messages
- 2,692
Um.... Anyone ever heard of ponzi scheme? Anyone see one recently? [emoji848][emoji39]
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Ok, I bought in a bit too early on Vanda (VNDA) but it is very oversold now.
It is trading at less than $500m with $350m in cash and about $240m in revenue from the two approved drugs, with a possibility of a 3rd approval soon.
I am pounding the table on this one. Just bought 6000 more shares in a IRA at $9.10
It is trading at less than $500m with $350m in cash and about $240m in revenue from the two approved drugs, with a possibility of a 3rd approval soon.
I am pounding the table on this one. Just bought 6000 more shares in a IRA at $9.10
bobandsherry
Thinks s/he gets paid by the post
- Joined
- Nov 24, 2015
- Messages
- 2,692
Based on the options, this one isn't showing a lot of love for upside movement. October $10 call shows basically no interest, no ask price. Nov $10 call just 30 cents with basically no interest either. Only decent interest is Dec $12 and $16 calls but small premium, seems to be a forgotten or ignored company.
However, someone could offer 50% premium to current price and cover half of the price just with the cash. Hhmmm....... time to take a second look.
Relief Therapeutics Holdings AG / Key word(s): Miscellaneous
23.09.2020 / 07:02
Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol
Geneva, Switzerland, and Radnor, PA, September 23, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announce that NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100(TM) aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments. RLF-100 is being developed by NeuroRx as part of a global partnership with Relief. The submission is based on a case-control study that compared patients who were treated with RLF-100(TM) (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with RLF-100(TM) demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement. Hypotension was seen in two aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed journal.
"The EUA application covers the same type of patients whom FDA has already allowed to receive treatment under the Expanded Access protocol authorized by the Agency in July. Tragically, we have found that many patients who might benefit from the Expanded Access protocol are hospitalized in centers that do not allow patients access to investigational drugs," said Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, "Our staff is working around the clock to address requests for RLF-100(TM) under the appropriate mechanism. All too often, patients of color and those of lower socioeconomic status are denied access."
FDA's guidance to industry identifies the criteria for EUA as safe and "may be effective," in contrast to the far more stringent requirement of "safe and effective" required for traditional drug approval. EUA may only be granted in circumstances where the Secretary of Health and Human Services has declared a Public Health Emergency, as is true in the COVID-19 pandemic.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We continue to work tirelessly with our partner NeuroRx to bring this potentially life-saving drug to patients afflicted with severe complications of COVID-19 infection as quickly as possible. The pursuit of EUA status is a crucial component of this effort."
23.09.2020 / 07:02
Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol
Geneva, Switzerland, and Radnor, PA, September 23, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announce that NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100(TM) aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments. RLF-100 is being developed by NeuroRx as part of a global partnership with Relief. The submission is based on a case-control study that compared patients who were treated with RLF-100(TM) (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with RLF-100(TM) demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement. Hypotension was seen in two aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed journal.
"The EUA application covers the same type of patients whom FDA has already allowed to receive treatment under the Expanded Access protocol authorized by the Agency in July. Tragically, we have found that many patients who might benefit from the Expanded Access protocol are hospitalized in centers that do not allow patients access to investigational drugs," said Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, "Our staff is working around the clock to address requests for RLF-100(TM) under the appropriate mechanism. All too often, patients of color and those of lower socioeconomic status are denied access."
FDA's guidance to industry identifies the criteria for EUA as safe and "may be effective," in contrast to the far more stringent requirement of "safe and effective" required for traditional drug approval. EUA may only be granted in circumstances where the Secretary of Health and Human Services has declared a Public Health Emergency, as is true in the COVID-19 pandemic.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We continue to work tirelessly with our partner NeuroRx to bring this potentially life-saving drug to patients afflicted with severe complications of COVID-19 infection as quickly as possible. The pursuit of EUA status is a crucial component of this effort."
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Vanda trading up (admittedly on very low volume) to $9.64, which feels better than $9.10 for sure but still a long way from the $12 to $15 area it should be trading in.
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
I am not going to touch it but I do wish you the best of luck in it and feel free to update success/failure!
Yeah, I'm in at $9.32, so I'll take the 3% gain in less than 24 hours. Decent start.
bobandsherry
Thinks s/he gets paid by the post
- Joined
- Nov 24, 2015
- Messages
- 2,692
Up 50 cents is better than down
I jumped in at $9.19 so 9 cents to the worse than you... This stock just seems to be unusually priced, will keep money on the line as long as you are rolling the bones 
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
It is still low volume.
We get a tiny bit of positive news and it will fly on decent volume. It doesn't even need a buyout, just going back to 52 week high would make it almost a double.
We get a tiny bit of positive news and it will fly on decent volume. It doesn't even need a buyout, just going back to 52 week high would make it almost a double.
I jumped in for 1000 shares at .47. Sold a day later at .52.
That’s great! I’m holding long, but there’s been a lot of opportunities to day trade this stock. Currently share price is over .62.
Another follower to the thread. Currently in or still in on Vnda 200 shares and 8 long contracts at 8, EXEL 4 long contracts at 15, CLSN 800 shares, and IONS 2 long contracts at 45. Although not part of this discussion I also have some BMY in the drug space which I have been planning to exit for some time. I am not in on RLFTF at least not now. IMO seems like more of a lottery stock trying to take advantage of the pandemic. Appears to be only public since mid June?? Couldn't find an IPO listing, but also couldn't find data at TDA prior to that. Could have bought up until the end of July for $0.02 / share! Will continue to follow.
It’s also traded on the Swiss stock exchange under rlf.sw, I think they brought it over to otc when they started seeing positive results. CEO has said they plan to uplist to Nasdaq or NYSE. I hope the share price rises so they won’t have to do a split to reach price requirements. Only positive to a split would be that outstanding shares would decrease to a normal level.
Sunset
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
I missed out on the ITCI fun, due to a LOT of procrastination...
This time I'm in VNDA for 200 and CLSN for 300.
This time I'm in VNDA for 200 and CLSN for 300.
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
CLSN is kind of risky right now, although it is trading at cash so definitely is a decent lotto ticket. I no longer think they will be able to convince FDA of approval of thermodox, but they do have the ovarian cancer drug.
The whole market is getting somewhat trounced right now. Some babies being thrown out with the bath water for sure.
The whole market is getting somewhat trounced right now. Some babies being thrown out with the bath water for sure.
Sunset
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Did you buy back into SGMO ?
Fermion
Give me a museum and I'll fill it. (Picasso) Give me a forum ...
Yeah, bought 1000 shares at $9.90 yesterday. It went lower than that.
bobandsherry
Thinks s/he gets paid by the post
- Joined
- Nov 24, 2015
- Messages
- 2,692
ITCI had a good run, but last 5 days hasn't been kind. Glad I unloaded everything and locked in the profits. Will keep an eye on this for possible re-entry point.
Similar threads
